This study further confirmed the requirement for the combination of IL-2 or IL-15 with anti-CD40 mAb for tumor regression versus the partial effects seen with anti-CD40 mAb treatment alone in large tumor burdens [29]. The gene discussed is IL2; the disease is neoplasm.